Publisher
Springer Science and Business Media LLC
Reference4 articles.
1. Baselga J, Tripathy D, Mendelsohn et al.: Phase II study of weekly, intravenous, recombinant, humanized anti-p185 Her-2 monoclonal antibody in patients with Her 2/neu overexpressing metastatic breast cancer. J Clin Oncol 14: 737–744, 1996
2. Cobleigh MA, Vogel CL, Tripathy D et al.: Multinational study of the efficacy and safety of humanized anti-Her-2 monoclonal antibody in women who have Her-2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639–2648, 1999
3. Vogel CL, Cobleigh MA, Tripathy D et al.: Efficacy and safety of trastuzumab as a single agent in first line treatment of Her-2 overexpressing metastatic breast cancer. J Clin Oncol 120: 719–726, 2002
4. Carbonell-Castellon X, Casteneda-Soto NJ, Clemens M et al.: Efficacy and safety of 3 weekly Herceptin monotherapy in women with Her-2 positive metastatic breast cancer: preliminary report from a phase II study. Proc Am Soc Clin Oncol 21: 19a, 2002 (abstract 73)
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献